| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Synmosa Biopharma Corporation (TWO: 4114)
4114 Technical Analysis
4
| As on 7th Nov 2025 4114 STOCK Price closed @ 33.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 36.29 & Strong Sell for SHORT-TERM with Stoploss of 40.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
4114STOCK Price
| Open | 33.30 | Change | Price | % |
| High | 33.55 | 1 Day | -0.50 | -1.49 |
| Low | 32.95 | 1 Week | -0.60 | -1.79 |
| Close | 33.00 | 1 Month | -1.70 | -4.90 |
| Volume | 999789 | 1 Year | -7.25 | -18.01 |
| 52 Week High 41.70 | 52 Week Low 29.10 | ||||
TWO Taiwan Most Active Stocks
| 1815 | 75.00 | -6.25% |
| 8088 | 46.80 | 9.99% |
| 8096 | 53.50 | -3.08% |
| 5498 | 25.50 | -0.39% |
| 8111 | 66.50 | -1.63% |
| 6274 | 380.00 | -4.40% |
| 8054 | 127.50 | 2.41% |
| 5371 | 91.50 | -3.89% |
| 5289 | 456.00 | 0.22% |
| 6548 | 41.45 | -0.36% |
TWO Taiwan Top Gainers Stocks
TWO Taiwan Top Losers Stocks
| 4114 Daily Charts |
4114 Intraday Charts |
Whats New @ Bazaartrend |
4114 Free Analysis |
|
|
4114 Important Levels Intraday
| RESISTANCE | 34.16 |
| RESISTANCE | 33.79 |
| RESISTANCE | 33.56 |
| RESISTANCE | 33.33 |
| SUPPORT | 32.67 |
| SUPPORT | 32.44 |
| SUPPORT | 32.21 |
| SUPPORT | 31.84 |
4114 Forecast November 2025
| 4th UP Forecast | 37.72 |
| 3rd UP Forecast | 36.21 |
| 2nd UP Forecast | 35.27 |
| 1st UP Forecast | 34.34 |
| 1st DOWN Forecast | 31.66 |
| 2nd DOWN Forecast | 30.73 |
| 3rd DOWN Forecast | 29.79 |
| 4th DOWN Forecast | 28.28 |
4114 Weekly Forecast
| 4th UP Forecast | 35.02 |
| 3rd UP Forecast | 34.37 |
| 2nd UP Forecast | 33.97 |
| 1st UP Forecast | 33.57 |
| 1st DOWN Forecast | 32.43 |
| 2nd DOWN Forecast | 32.03 |
| 3rd DOWN Forecast | 31.63 |
| 4th DOWN Forecast | 30.98 |
4114 Forecast2025
| 4th UP Forecast | 58.24 |
| 3rd UP Forecast | 50.15 |
| 2nd UP Forecast | 45.14 |
| 1st UP Forecast | 40.14 |
| 1st DOWN Forecast | 25.86 |
| 2nd DOWN Forecast | 20.86 |
| 3rd DOWN Forecast | 15.85 |
| 4th DOWN Forecast | 7.76 |
Synmosa Biopharma Corporation ( TWO Taiwan Symbol : 4114 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
4114 Business Profile
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, and other forms. It also offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei City, Taiwan. Address: No. 396, Neihu Road, Taipei, Taiwan, 114
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service